We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+9.33%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$899M
AUM Growth
+$212M
Cap. Flow
+$125M
Cap. Flow %
13.86%
Top 10 Hldgs %
65.2%
Holding
49
New
13
Increased
20
Reduced
8
Closed
8

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$146M
2
AGN
Allergan plc
AGN
+$37.1M
3
UHS icon
Universal Health Services
UHS
+$16.5M
4
CNC icon
Centene
CNC
+$15.4M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$9.07M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$44.9M
2
AMGN icon
Amgen
AMGN
+$28.7M
3
NVRO
NEVRO CORP.
NVRO
+$28M
4
CI icon
Cigna
CI
+$23.4M
5
STJ
St Jude Medical
STJ
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 87.72%
2 Financials 6.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHC icon
1
Bausch Health
BHC
$1.75B
$132M 14.68%
+1,299,056
New +$146M
NVRO
2
DELISTED
NEVRO CORP.
NVRO
$114M 12.63%
1,682,877
-522,304
-24% -$28M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$36.1B
$84.1M 9.35%
1,281,189
+66,695
+5% +$4.12M
AET
4
DELISTED
Aetna Inc
AET
$57.9M 6.44%
535,532
+42,128
+9% +$4.55M
VTRS icon
5
Viatris
VTRS
$19.8B
$42.5M 4.72%
785,284
-933,900
-54% -$44.9M
AGN
6
DELISTED
Allergan plc
AGN
$38.9M 4.33%
+124,500
New +$37.1M
TVTY
7
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$32.5M 3.61%
2,525,044
+406,007
+19% +$4.94M
STJ
8
DELISTED
St Jude Medical
STJ
$31.3M 3.48%
506,900
-363,400
-42% -$22.9M
CNCE
9
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$27.2M 3.02%
1,432,617
-213,056
-13% -$4.63M
BIIB icon
10
Biogen
BIIB
$29.5B
$26.4M 2.94%
86,300
-3,200
-4% -$920K
MNK
11
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$21.8M 2.42%
291,940
-138,260
-32% -$9.31M
ACOR
12
DELISTED
Acorda Therapeutics
ACOR
$21.6M 2.4%
4,202
+1,996
+90% +$8.72M
ANIP icon
13
ANI Pharmaceuticals
ANIP
$1.77B
$20.5M 2.28%
453,852
+183,812
+68% +$7.91M
TVTX icon
14
Travere Therapeutics
TVTX
$5.16B
$20.4M 2.27%
1,058,882
+336,782
+47% +$6.73M
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$19M 2.11%
352,924
-203,300
-37% -$10.3M
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
$18.4M 2.05%
557,170
+7,270
+1% +$246K
CNC icon
17
Centene
CNC
$32.5B
$17.1M 1.9%
+520,000
New +$15.4M
SPNC
18
DELISTED
Spectranetics Corp
SPNC
$16.5M 1.83%
1,092,512
+70,000
+7% +$924K
UHS icon
19
Universal Health Services
UHS
$9.12B
$16.2M 1.8%
+135,200
New +$16.5M
INSM icon
20
Insmed
INSM
$23.2B
$12.5M 1.39%
689,107
+113,700
+20% +$2M
FOMX
21
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$12.1M 1.35%
1,497,431
+633,023
+73% +$4.73M
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.24B
$11M 1.22%
93,005
+6,440
+7% +$639K
ELOS
23
DELISTED
Syneron Medical Ltd
ELOS
$10.8M 1.21%
1,406,282
+214,772
+18% +$1.64M
CORI
24
DELISTED
Corium International, Inc.
CORI
$10.7M 1.19%
1,321,479
+116,758
+10% +$918K
DERM
25
DELISTED
Dermira, Inc.
DERM
$8.57M 0.95%
247,500
-47,800
-16% -$1.37M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q4 2015 Portfolio in Review

As of Q4 2015, Senzar Asset Management held 49 positions worth $899M, up 31% from $687M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Senzar Asset Management deployed $125M of net new capital in Q4 2015, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was Bausch Health: 1,299,056 shares worth $132M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Viatris, an estimated $44.9M trimmed.

  • Senzar Asset Management's largest Q4 2015 buy was Bausch Health: 1,299,056 shares worth $132M.
  • Senzar Asset Management added most to Acorda Therapeutics in Q4 2015, an estimated $8.72M increase.
  • Senzar Asset Management's biggest Q4 2015 reduction was Viatris, cutting an estimated $44.9M.
  • Senzar Asset Management fully exited Amgen in Q4 2015, selling an estimated $28.7M.
  • Senzar Asset Management's ten largest holdings make up 65% of its $899M portfolio in Q4 2015.
  • Senzar Asset Management opened 13 new positions and closed 8 in Q4 2015.
  • Senzar Asset Management's portfolio value rose 31% quarter-over-quarter to $899M.

Based on Senzar Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.